ArticlePloS one2025
Green synthesis of silver nanoparticles from Brownlowia tersa leaf extract: multifaceted evaluation of antibacterial, antioxidant, cytotoxic, and anti-alzheimer potential.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports the first green synthesis of silver nanoparticles (AgNPs) using an aqueous leaf extract of Brownlowia tersa (B. tersa), confirming their formation via UV-Vis spectrophotometry with a peak at 472 nm. The AgNPs were evaluated for their antimicrobial and neuroprotective activities, particularly for Alzheimer's disease. GC-MS and FT-IR analyses identified phenolics and flavonoids as the capping and reducing agents in the synthesis process. FESEM imaging showed nanoparticles of varied shapes and sizes, while EDX analysis confirmed the presence of silver, oxygen, and carbon. The antimicrobial activity was demonstrated with inhibition zones ranging from 8.5 to 10.5 mm against Staphylococcus aureus, Bacillus cereus, Shigella flexneri, and Pseudomonas aeruginosa at concentrations of 100 and 200 μg/disc, compared to control, deionised water. In antioxidant assays, AgNPs exhibited an IC₅₀ of 1533.448 μg/ml, significantly higher than L-ascorbic acid (IC₅₀: 83.948 μg/ml) and the plant extract (IC₅₀: 254.438 μg/ml), indicating weaker antioxidant properties of AgNPs. The cytotoxicity of the AgNPs was assessed using the brine shrimp lethality test, yielding LC₅₀ value of 13.50 μg/ml, indicating moderate toxicity. Neuropharmacological tests, except the elevated plus maze, on swiss albino mice revealed significant anxiolytic effects (p < 0.05) and enhanced locomotor activity. Molecular docking studies of bioactive compounds from B. tersa leaves with Alzheimer's and bacterial infection-related proteins revealed binding energies from -7.7 to -5.2 kcal/mol, with Benzamide, N-ethyl-N-[(4-ethylaminophenyl) sulfonyl]- and 3,4-Dihydroxyphenylglycol showing the strongest affinities. While the results are promising, the study acknowledges challenges in scaling up the synthesis process and emphasises the need for further research into the long-term biological effects and safety of AgNPs. Overall, B. tersa-derived AgNPs show great potential for therapeutic applications in bacterial infections and neurological disorders, but scalability and safety require more investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.